




RealRate

# PHARMACEUTICAL 2023

Spero Therapeutics Inc.  
Rank 215 of 446





# PHARMACEUTICAL 2023

Spero Therapeutics Inc.  
Rank 215 of 446



The relative strengths and weaknesses of Spero Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Spero Therapeutics Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 38% points. The greatest weakness of Spero Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 97%, being 54% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	113,570
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,649
Liabilities, Non-Current	4,957
Other Assets	10,864
Other Compr. Net Income	2.0
Other Expenses	11,630
Other Liabilities	22,262
Other Net Income	-4,218
Other Revenues	53,509
Property and Equipment	368
Research and Development	47,593
Selling, General and Administrative Expense	36,483

Output Variable	Value in 1000 USD
Assets	124,802
Liabilities	48,868
Expenses	95,706
Revenues	53,509
Stockholders Equity	75,934
Net Income	-46,415
Comprehensive Net Income	-46,414
Economic Capital Ratio	97%